{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:15:28Z","timestamp":1783577728973,"version":"3.55.0"},"reference-count":20,"publisher":"Editorial Committee of Japanese Journal of Infectious Diseases, National Institute of Infectious Dis","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn J Infect Dis"],"published-print":{"date-parts":[[2026,1,30]]},"DOI":"10.7883\/yoken.jjid.2025.170","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T22:10:31Z","timestamp":1769724631000},"source":"Crossref","is-referenced-by-count":1,"title":["Susceptibility to cefiderocol and other novel antibiotics against carbapenem-non-susceptible gram-negative bacilli"],"prefix":"10.7883","author":[{"given":"Teruko","family":"Ohkura","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, Nagoya University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Watarai","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Nagoya University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Takekoshi","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Nagoya University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeko","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Nagoya University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Osada","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Nagoya University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Morioka","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagoya University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Konan Kosei Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Oka","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagoya University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagoya University Hospital, Japan"},{"name":"Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4631","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Doi Y. Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis 2019;69:S565\u201375. https:\/\/doi.org\/10.1093\/cid\/ciz830","DOI":"10.1093\/cid\/ciz830"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ito A, Sato T, Ota M, et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against gram-negative bacteria. Antimicrob Agents Chemother 2018;62:e01454\u201317. https:\/\/doi.org\/10.1128\/aac.01454-17","DOI":"10.1128\/AAC.01454-17"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hackel MA, Tsuji M, Yamano Y, et al. Activity of the siderophore cephalosporin, cefiderocol, against a recent collection of clinically relevant gram-negative bacilli from North America and Europe, including carbapenem-nonsusceptible isolates (SIDERO-WT-2014 Study). Antimicrob Agents Chemother 2017;61:e00093\u201317. https:\/\/doi.org\/10.1128\/aac.00093-17","DOI":"10.1128\/AAC.00093-17"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Karlowsky JA, Hackel MA, Tsuji M, et al. In Vitro Activity of cefiderocol, a siderophore cephalosporin, against gram-negative bacilli isolated by clinical laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015. Int J Antimicrob Agents 2019;53:456\u201366. https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.11.007","DOI":"10.1016\/j.ijantimicag.2018.11.007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hsueh SC, Lee YJ, Huang YT, et al. In vitro activities of cefiderocol, ceftolozane\/tazobactam, ceftazidime\/avibactam and other comparative drugs against imipenem-resistant <i>Pseudomonas aeruginosa<\/i> and <i>Acinetobacter baumannii<\/i>, and <i>Stenotrophomonas maltophilia,<\/i> all associated with bloodstream infections in Taiwan. J Antimicrob Chemother 2019;74:380\u20136. https:\/\/doi.org\/10.1093\/jac\/dky425","DOI":"10.1093\/jac\/dky425"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ma J, Song X, Li M, et al. Global spread of carbapenem-resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy. Microbiol Res 2023;266:127249. https:\/\/doi.org\/10.1016\/j.micres.2022.127249","DOI":"10.1016\/j.micres.2022.127249"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kayama S, Kawakami S, Kondo K,et al. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance. J Glob Antimicrob Resist 2024;38:12\u201320. https:\/\/doi.org\/10.1016\/j.jgar.2024.05.009","DOI":"10.1016\/j.jgar.2024.05.009"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Sakoh T, Miyajima E, Endo Y, et al. Cefiderocol susceptibility of 146 Stenotrophomonas maltophilia strains clinically isolated from blood in two Japanese hospitals over a 10-year period. Eur J Clin Microbiol Infect Dis 2024;43:2485\u20138. https:\/\/doi.org\/10.1007\/s10096-024-04960-2","DOI":"10.1007\/s10096-024-04960-2"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hopkins KL, Meunier D, Naas T, et al. Evaluation of the NG-Test CARBA 5 multiplex immunochromatographic assay for the detection of KPC, OXA-48-like, NDM, VIM and IMP carbapenemases. J Antimicrob Chemother. 2018;73:3523-3526. https:\/\/doi.org\/10.1093\/jac\/dky342.","DOI":"10.1093\/jac\/dky342"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wachino J, Doi Y, Yamane K, et al. Molecular characterization of a cephamycin-hydrolyzing and inhibitor-resistant class A b-lactamase, GES-4, possessing a single G170S substitution in the \u03a9-loop. Antimicrob Agents Chemother 2004;48:2905\u20132910. https:\/\/doi.org\/10.1128\/AAC.48.8.2905\u20132910.2004","DOI":"10.1128\/AAC.48.8.2905-2910.2004"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Guiterrez O, Juan C, Cercenado E, et al. Molecular epidemiology and mechanisms of carbapenem resistance in <i>Pseudomonas aeruginosa<\/i> isolates from Spanish hospitals. Antimicrob Agents Chemother 2007;51:4329\u20134335. https:\/\/doi.org\/10.1128\/AAC.00810-07.","DOI":"10.1128\/AAC.00810-07"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kaase M, Nordmann P, Wichelhous TA, et al. NDM-2 carbapenemase in <i>Acinetobacter baumannii<\/i> from Egypt. J Antimicrob Chemother 2011;66:1260\u20131262. https:\/\/doi.org\/10.1093\/jac\/dkr135.","DOI":"10.1093\/jac\/dkr135"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem hydrolyzing KPC-2 and inhibitor-resistant TEM-30 b-lactamases in New York City. Clin Infect Dis. 2004;39:55-60.","DOI":"10.1086\/421495"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Aoki W, Uwamino Y, Niida N, et al. Cefiderocol susceptibility of <i>Stenotrophomonas maltophilia<\/i> species complex and carbapenem-resistant <i>Pseudomonas aeruginosa<\/i> isolates from blood cultures at a university hospital in Tokyo, Japan. J Global Antimicrob Resist. 2025;44:251-255.","DOI":"10.1016\/j.jgar.2025.07.004"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Murata K, Kosai K, Mitsumoto-Kaseida F, et al. Antimicrobial susceptibility and resistance mechanis\u3002ms to antipseudomonal \u03b2-lactams in <i>Pseudomonas aeruginosa<\/i> isolates from blood. Microbiol Spectr. 2025;13(5) https:\/\/10.1128\/spectrum.02790-24.","DOI":"10.1128\/spectrum.02790-24"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Yanagihara K, Kurihara D, Kimata M. Tazobactam\/ceftolozane (TAZ\/CTLZ) and relebactam\/imipenem (REL\/ IPM) susceptibility in Japan: Nationwide surveillance of respiratory bacterial pathogens in 2019\/20. J Infect Chemother. 2025;31:102569. https:\/\/doi.org\/10.1016\/j.jiac.2024.11.019.","DOI":"10.1016\/j.jiac.2024.11.019"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Fournier D, Carri\u00e8re R, Bour M et al. Mechanisms of resistance to Ceftolozane\/Tazobactam in <i>Pseudomonas aeruginosa<\/i>: Results of the GERPA multicenter study. Antimicrob Agents Chemother. 65:e01117-20. https:\/\/doi.org\/10.1128\/AAC.01117-20.","DOI":"10.1128\/AAC.01117-20"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Bostanghadiri N, Sholeh M, Navidifar T, et al. Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob 2024;23:26. https:\/\/doi.org\/10.1186\/s12941-024-00685-4","DOI":"10.1186\/s12941-024-00685-4"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Simmer PJ, Beisken S, Bergman Y, et al. Cefiderocol activity against clinical <i>Pseudomonas aeruginosa<\/i> isolates exhibiting ceftolozane-tazobactam resistance. Open Forum Infect Dis. 2021. DOI: 10.1093\/ofid\/ofab311 https:\/\/doi.org\/10.1093\/ofid\/ofab311","DOI":"10.1093\/ofid\/ofab311"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Gomis-Font MA, Sastre-Femenia MA, Taltavull B, et al. <i>In vitro<\/i> dynamics and mechanisms of cefiderocol resistance development in wild-type, mutator and XDR <i>Pseudomonas aeruginosa<\/i>. J Antimicrob Chemother 2023; <b>78<\/b>: 1785\u20131794. https:\/\/doi.org\/10.1093\/jac\/dkad172","DOI":"10.1093\/jac\/dkad172"}],"container-title":["Japanese Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2025.170\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T03:23:08Z","timestamp":1769829788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/yoken\/advpub\/0\/advpub_JJID.2025.170\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7883\/yoken.jjid.2025.170","relation":{},"ISSN":["1344-6304","1884-2836"],"issn-type":[{"value":"1344-6304","type":"print"},{"value":"1884-2836","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"article-number":"JJID.2025.170"}}